Entrar/Registro  
INICIO ENGLISH
 
Medicina Cutánea Ibero-Latino-Americana
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio


ENVÍO DE ARTÍCULOS






>Revistas >Medicina Cutánea Ibero-Latino-Americana >Año 2010, No. 4


Darwich E, Herrero C
Utilidad clínica de los anticuerpos en las enfermedades autoinmunes del tejido conectivo
Med Cutan Iber Lat Am 2010; 38 (4)

Idioma: Español
Referencias bibliográficas: 43
Paginas: 143-156
Archivo PDF: 152.67 Kb.


Texto completo




RESUMEN

Los laboratorios de inmunología clínica tienen un papel fundamental en el proceso diagnóstico de las enfermedades autoinmunes del tejido conectivo. Algunos autoanticuerpos se consideran específicos de una determinada entidad y se utilizan como marcadores de la misma. Además, algunos de estos autoanticuerpos estan asociados con síndromes clínicos específicos o subgrupos de la enfermedad, siendo útiles en la evaluación del compromiso orgánico y en la predicción de su pronóstico. En este artículo se realiza una revisión de la utilidad clínica de los autoanticuerpos descritos en las enfermedades autoinmunes que tienen con frecuencia repercusión cutánea.


Palabras clave: Autoanticuerpos, lupus eritematoso sistémico, esclerosis sistémica, esclerodermia, dermatomiositis.


REFERENCIAS

  1. Sinico RA, Radice A. [The clinical immunology laboratory in diagnosis and monitoring of systemic lupus erythematosus and connective tissue diseases]. G Ital Nefrol 2005; 33: S21-6.

  2. Kurien BT, Scofield RH. Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand J Immunol 2006; 64: 227-35.

  3. Yamasaki Y, Narain S, Yoshida H, Hernández L, Barker T, Hahn PC et al. Autoantibodies to RNA helicase A: a new serologic marker of early lupus. Arthritis Rheum 2007; 56: 596-604.

  4. Kavanaugh AF, Solomon DH. American College of Rheumatology ad hoc committee on immunologic testing guidelines. Guidelines for immunologic laboratory testing in the rheumaticdiseases: anti-DNA antibody tests. Arthritis Rheum 2002; 47: 546-55.

  5. Rekvig OP, Nossent JC. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus. Arthritis Rheum 2003; 48: 300-12.

  6. Haugbro K, Nossent JC, Winkler T, Figenschau Y, Rekvig OP. Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversity. Ann Rheum Dis 2004; 63: 386-94.

  7. Moura CG, Lima I, Barbosa L, Athanazio D, Reis E, Reis M. Anti-C1q antibodies: association with nephritis and disease activity in systemic lupus erythematosus. J Clin Lab Anal 2009; 23: 19-23.

  8. Souza A, Da Silva LM, Oliveira FR, Roselino AM, Louzada-Junior P. Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease. Lupus 2009; 18: 223-9.

  9. Sun XY, Shi J, Han L, Su Y, Li ZG. Anti-histones antibodies in systemic lupus erythematosus: prevalence and frequency in neuropsychiatric lupus. J Clin Lab Anal 2008; 22: 271-7.

  10. Muller S, Dieker J, Tincani A, Meroni PL. Pathogenic anti-nucleosome antibodies. Lupus 2008; 17: 431-6.

  11. Keith MP, Moratz C, Tsokos GC. Anti-RNP immunity: implications for tissue injury and the pathogenesis of connective tissue disease. Autoimmun Rev 2007; 6: 232-6.

  12. Ni JD, Yao X, Pan HF, Li XP, Xu JH, Ye DQ. Clinical and serological correlates of anti-Sm autoantibodies in Chinese patients with systemic lupus erythematosus: 1,584 cases. Rheumatol Int 2009; 29: 1323-6.

  13. Meyer O. Anti-SSA/Ro and anti-SSB/La antibodies. What’s new? Ann Med Interne (Paris) 2002; 153: 520-9.

  14. Agarwal S, Harper J, Kiely PD. Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus. Lupus 2009; 18: 407-12.

  15. Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airò P, Cattaneo R, Franceschini F. Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. Lupus 2008; 17: 727-32.

  16. Gryga K, Milewski M, Zółci ski M, Dyczek A, Musiał J. Anti-Ku autoantibodies: series of 5 cases. Pol Arch Med Wewn 2009; 119: 95-7.

  17. Shirahama S, Furukawa F, Yagi H, Tanaka T, Hashimoto T, Takigawa M. Bullous systemic lupus erythematosus: detection of antibodies against noncollagenous domain of type VII collagen. J Am Acad Dermatol 1998; 38: 844-8.

  18. Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996; 22: 709-35.

  19. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989-2003.

  20. Reveille JD, Solomon DH, American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49: 399-412.

  21. Raijmakers R, Renz M, Wiemann C, Egberts WV, Seelig HP, Van Venrooij WJ et al. PM-Scl- 75 is the main autoantigen in patients with thepolymyosites/scleroderma overlap syndrome. Arthritis Rheum 2004; 50: 565-9.

  22. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 35-42.

  23. Meyer O. Prognostic markers for systemic sclerosis. Joint Bone Spine 2006; 73: 490-4.

  24. Hara T, Ogawa F, Muroi E, Komura K, Takenaka M, Hasegawa M et al. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis. J Rheumatol 2008; 35: 451-7.

  25. Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ. Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol 2007; 34: 1528-34.

  26. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senecal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007; 9: R78.

  27. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009; 48: 607-12.

  28. Gunawardena H, Betteridge ZE, McHugh NJ. Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol 2008; 20: 675-80.

  29. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 2007; 46: 1005-8.

  30. Hashish L, Trieu EP, Sadanandan P, Targoff IN. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome (abstract). Arthritis Rheum 2005; 52: S312.

  31. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996; 26: 459-67.

  32. Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 233-41.

  33. Wedderburn LR, McHugh NJ, Chinoy H, Cooper RG, Salway F, Ollier WE et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology 2007; 46: 1786-91.

  34. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990; 33: 1361-70.

  35. Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutopoulos HM, Vencovsky J et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65: 1635–8.

  36. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985; 28: 796-803.

  37. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571-6.

  38. Sato S, Hoshino K, Satoh T, Suwa A, Hirakata M. MDA5 (melanoma-differentiationassociated gene 5) as an autoantigen recognised by anti-CADM-140 antibody in patients with clinically amyopathic dermatomyositis (abstract). Arthritis Rheum 2008; 58: S923.

  39. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O’Hanlon TP et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682-9.

  40. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 2007; 46: 25-8.

  41. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007; 56: 3132-7.

  42. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 2008; 47: 324-8.

  43. Gunawardena H, Betteridge ZE, McHugh NH. Newly identified autoantibodies: relationship to idiopathic inflammatory myophaty subsets and pathogenesis. Curr Opin Rheumatol 2008; 20: 675-80.



>Revistas >Medicina Cutánea Ibero-Latino-Americana >Año2010, No. 4
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019